← Back to Search

Topical CBD for Skin Health (cannabidiol Trial)

Q: Are there any open slots left for participation in this research endeavor?

<p>Per the information on clinicaltrials.gov, this particular medical study is not actively recruiting new participants. It was first posted on December 1st 2024 and last updated October 30th 2023; nevertheless, there are 27 other trials in search of patients right now.</p>

N/A

Waitlist Available

Research Sponsored by Penn State University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up ~5 hours

Awards & highlights

cannabidiol Trial Summary

This trial studied the effects of topical CBD on healthy adults, finding it may help with pain, recovery, and general wellness.

Who is the study for?

This trial is for English-speaking men and women aged 18 or older with a BMI ≤ 39.9 and normal blood sugar levels (HbA1C <6.5%). It's not suitable for those with diabetes, drug use, pregnant/breastfeeding women, abnormal heart rates/BP, skin conditions/allergies, nicotine users, or recent CBD users.Check my eligibility

What is being tested?

The study tests the effect of topical Cannabidiol (CBD) on skin vascular reactivity using iontophoresis in healthy adults. The goal is to see if CBD can reduce the increased blood flow response that happens when the skin is stimulated.See study design

What are the potential side effects?

While specific side effects are not listed for this trial, common side effects of topical CBD may include mild irritation at the application site. Since it's used externally and by healthy individuals here, significant side effects are less expected.

cannabidiol Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ ~5 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~~5 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and ~5 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cutaneous Vascular Conductance

Side effects data

From 2022 Phase 2 & 3 trial • 90 Patients • NCT04387617

38%

Tiredness

24%

Drowsiness

24%

Poor sleep

22%

Constipation

18%

Poor Appetite

16%

Dizziness

Headache

Diarrhea

Nausea

Itching

100%

80%

60%

40%

20%

Study treatment Arm

CBD Oil Group

Control Group

cannabidiol Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: CannabidiolExperimental Treatment1 Intervention

Active ingredient experimental arm, contains full spectrum connabidiol

Group II: PlaceboPlacebo Group1 Intervention

Vehicle control, does not contain cannabidiol

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cannabidiol

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Penn State UniversityLead Sponsor

355 Previous Clinical Trials

125,709 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open slots left for participation in this research endeavor?

"Per the information on clinicaltrials.gov, this particular medical study is not actively recruiting new participants. It was first posted on December 1st 2024 and last updated October 30th 2023; nevertheless, there are 27 other trials in search of patients right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Topical Cannabidiol Application and Skin Vascular Reactivity

Lacy Alexander 2024. "Topical Cannabidiol Application and Skin Vascular Reactivity". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05456113.

All > Cbd > Epidiolex